by Plasma protease C1-inhibitor treatment is used to treat hereditary angioedema (HAE) which is a rare genetic disorder characterized by recurrent episodes of severe swelling. It helps to reduce the face, intestinal tract, and airway swelling by regulating one of the primary biochemical pathways involved in inflammation and coagulation. The rising prevalence of HAE conditions globally drives the demand for plasma protease C1-inhibitor treatment. According to estimates, about 1 in 10,000 to 1 in 50,000 people are affected by HAE worldwide. The lack of proper diagnosis and treatment in developing nations also contributes to the growing market.
The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising healthcare expenditure in Asia Pacific and Latin America will boost the Plasma Protease C1-inhibitor Treatment Market growth over the forecast period. Growing partnerships between biopharma players and regional health authorities for improving diagnostic and treatment access in these emerging regions are also boosting the market demand. Adoption of innovative biologicals and orphan drugs for treating rare diseases will accelerate the plasma protease C1-inhibitor treatment uptake. Increasing approval of advanced plasma-derived therapies and upcoming pipeline products are expected to reshape the competitive landscape during 2023-2030.
Porter’s Analysis
Threat of new entrants: The barriers to entry in plasma protease C1-inhibitor treatment market are high due to large capital requirements for R&D and manufacturing facilities. Stringent regulatory requirements also discourage new entrants.
Bargaining power of buyers: The bargaining power of buyers in plasma protease C1-inhibitor treatment market is moderate as the treatment options are limited and buyers have to rely on few major established players.
Bargaining power of suppliers: Due to availability of limited number of suppliers for plasma and other raw materials, their bargaining power is high in the market. Suppliers can influence prices.
Threat of new substitutes: Threat of substitution is low as there are limited treatment alternatives available for managing angioedema attacks currently.
Competitive rivalry: The competitive rivalry in the market is high due to presence of few major players controlling majority market share. Players compete based on new product innovations and expansion to newer geographies.
Key Takeaways
The Global Plasma Protease C1-Inhibitor Treatment Market Demand is expected to witness high growth over the forecast period driven by increasing cases of hereditary angioedema. The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.
North America is projected to remain the dominant as well as the fastest growing regional market during the forecast period owing to well developed healthcare sector and spending, increasing patient awareness and availability of favorable reimbursement policies.
Key players operating in the plasma protease C1-inhibitor treatment market are CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc. CSL Behring LLC holds the major share in the market. Players are involved in new product approvals and launches to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
